MyPeptideMatchOverview
Sermorelin is a growth hormone-releasing hormone (GHRH) analog—a 29-amino-acid peptide that stimulates the pituitary gland to release growth hormone (GH). It was once FDA-approved under the brand name Geref for diagnosing and treating growth hormone deficiency; the manufacturer discontinued it in 2008 for commercial reasons, not because of safety or efficacy concerns. That distinction is important: because sermorelin was previously approved, it retains a pathway for legal compounding in the US under Category 1. Today, people seek sermorelin for growth hormone support, anti-aging, improved sleep, and body composition, often through integrative or longevity-oriented clinics.
Unlike some other growth hormone-related peptides (e.g., ipamorelin, CJC-1295), sermorelin has a clear regulatory path when obtained from a licensed 503A pharmacy using approved bulk substance. That makes it one of the few GH-stimulating peptides that can be offered legally in a compounding context.
How It Works (Mechanism of Action)
Sermorelin mimics growth hormone-releasing hormone (GHRH). When injected, it binds to receptors on the pituitary gland and prompts the release of growth hormone in a pulsatile, more natural pattern than giving GH directly. Growth hormone supports muscle mass, bone density, metabolism, and recovery. By stimulating the body’s own GH release, sermorelin is thought to produce a more physiologic profile while still increasing GH availability.
